The new biosimilar offers an additional treatment option for patients with multiple myeloma, bone metastases, and giant cell tumors of the bone.

FDA approval of Emcitate (tiratricol) offers the first targeted therapy for peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 deficiency.

Betzaida Tejada-Vera, from the National Center for Health Statistics in Hyattsville, Maryland, and colleagues used data from all death certificates filed in the 50 states and the District of Columbia ...

Associations included higher prevalence of focal to bilateral tonic-clonic seizures in drug-resistant epilepsy ...

Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.

The oral ALK2 inhibitor significantly reduced mean total new heterotopic ossification volume at 24 weeks in patients aged 12 ...

Supported by phase 3 OASIS-4 data, elinzanetant significantly reduced daily hot flash frequency in women receiving endocrine therapy for HR-positive breast cancer.

Modest decline seen in 30-day case fatality rates over time among young adults, driven by intracerebral hemorrhage, subarachnoid hemorrhage.

Daiichi Sankyo and Merck have voluntarily withdrawn their application for ifinatamab deruxtecan in pretreated extensive-stage small cell lung cancer following feedback from the FDA regarding phase 2 ...

Phase 3 trial data show significant scalp, eyelash, and eyebrow hair regrowth at 36 weeks in adolescents treated with oral baricitinib.

Advisers split on whether Galleri, which screens for more than 50 cancers, catches disease early enough to save lives.

The FDA has accepted and granted Priority Review to an application for lower doses of leniolisib to treat younger children with activated phosphoinositide 3-kinase delta syndrome.